1131 Anti-CLEC2D-TLR9 agonist conjugate binds to and internalizes CLEC2D on myeloid cells, plasmacytoid DCs and B cells leading to robust TLR pathway activation and inflammatory cytokine production

• Xianzhe Wang,
• Shruti Malu,
• Vandana Nandivada,
• Ming Tang,
• Seng-Lai Tan,
• Kelly Nichols,
• Siamak Tabrizi,
• Frano Irvine,
• Caitlin Goshert,
• Elizabeth Scanlon,
• Matthew Huggins,
• Heather Flick

Affiliations

Xianzhe Wang

1Immunitas Therapeutics, Waltham, MA, USA

Shruti Malu

Aff1 grid.240145.60000000122914776Department of Melanoma Medical OncologyUniversity of Texas MD Anderson Cancer Center Houston TX USA

Vandana Nandivada

1The University of Texas MDACC, Houston, USA

Ming Tang

1Immunitas Therapeutics, Waltham, MA, USA

Seng-Lai Tan

4Bicara Therapeutics Limited, Cambridge, MA, USA

Kelly Nichols

School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, USA

Siamak Tabrizi

1Immunitas Therapeutics, Waltham, MA, USA

Frano Irvine

1Immunitas Therapeutics, Waltham, MA, USA

Caitlin Goshert

1Immunitas Therapeutics, Waltham, MA, USA

Elizabeth Scanlon

1Immunitas Therapeutics, Waltham, MA, USA

Matthew Huggins

1Immunitas Therapeutics, Waltham, MA, USA

Heather Flick

1Immunitas Therapeutics, Waltham, MA, USA